Also known as: AIDS
AIDS is the advanced stage of HIV infection characterized by severe immune suppression and susceptibility to opportunistic infections and cancers.
The 340B Drug Pricing Program faces scrutiny after a Florida fraud case and data showing hospitals earn billions in profits. Lawmakers propose new accountability measures, while hospital advocates defend its role in funding community care.
The FDA has accepted Gilead's New Drug Application for the investigational once-daily HIV regimen bictegravir/lenacapavir and granted priority review, with a PDUFA action date of August 27, 2026. The filing is supported by Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing comparable efficacy in maintaining virological suppression. If approved, BIC/LEN would be the smallest single-tablet regimen for HIV treatment.
Maryland biotech leaders outlined a strategy to scale the state's life sciences ecosystem, focusing on community building, investor attraction, and federal alignment. Meanwhile, 18 states face limited access to HIV treatment assistance programs due to stagnant federal funding amid rising costs.
Lenacapavir was launched in Zimbabwe in February 2026 as Kenya became the fourth African country to start administering the twice-yearly HIV prevention injection. The rollout follows launches in Eswatini and Zambia in December 2025, five months after US FDA approval.
A once-daily single-tablet combination of bictegravir and lenacapavir demonstrated non-inferiority to existing HIV treatments in Phase 3 trials, offering simplified treatment for people living with HIV who are virologically suppressed.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07696169 |
Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers |
NOT_YET_RECRUITING | |
| NCT07579247 |
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07032363 |
Implementing Depression and Adherence Treatment |
RECRUITING | NA |
| NCT06585631 |
The Collaborative Care PrTNER Study |
RECRUITING | NA |
| NCT06045923 |
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV |
TERMINATED | |
| NCT04770701 |
Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes |
WITHDRAWN | PHASE4 |
| NCT03670316 |
Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care |
COMPLETED | PHASE4 |
